The group stated that the proposed restructuring includes consolidating every 10 shares into 1 share, with PC investing HK$80 million to subscribe for 212 million new consolidated shares at HK$0.37736 per share, representing approximately 66.55% of the enlarged share capital. The group's closing price before suspension was HK$0.06. Assuming the consolidated shares take effect, the adjusted closing price would be HK$0.60, representing a discount of approximately 37.11% on the issue price. The proceeds raised, approximately HK$30 million, will be used to repay debts owed to creditors under the creditors' scheme, approximately HK$10 million will be used to settle the costs of the proposed restructuring, and approximately HK$40 million will be used for general working capital purposes. PC must grant the group an unsecured, interest-free loan of HK$8 million to cover professional fees related to the proposed restructuring and subscription matters.
*Proposal Involves Debt Restructuring and Change in Board Lot Size*
In addition, the group stated that the proposed restructuring also includes debt restructuring through a creditors' scheme and a change in the board lot size.
The group noted that Liu Huiyi was formerly an executive director of Kangjian International Medical (03886) and is currently the CEO of Shangbentang Holistic Scientific Research, while Huang Shijie, who has previously engaged in legal practice, is admitted as a Hong Kong barrister and solicitor. (wh)